Re: Amendment re Initial Indication 2 in the U.S. IGF-1 Agreementu.s. Igf-1 Agreement • August 2nd, 2007 • Tercica Inc • Pharmaceutical preparations
Genentech, Inc. (“Genentech”) and Tercica, Inc. (“Tercica”) are parties to that certain License and Collaboration Agreement, effective as of April 15, 2002, as amended (“U.S. IGF-1 Agreement”) and that certain International License and Collaboration Agreement, effective as of July 25, 2003, as amended (“International IGF-1 Agreement”), pursuant to which Tercica licensed from Genentech certain rights to develop and commercialize IGF-1 in the United States and in all foreign countries, respectively, (such agreements, collectively, the “IGF-1 Agreements”). All capitalized terms not otherwise defined herein shall have the meanings defined in the U.S. IGF-1 Agreement.
